Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-10-09
2007-10-09
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S248000, C544S105000, C544S236000
Reexamination Certificate
active
10499179
ABSTRACT:
Fused pyradazine derivatives which are usefule as CDK inhibitors are described herein. The described invention alos includes methods of making such fused pyradazine derivatives as wells as methods of using the same in the treatment of hyperproliferative diseases.
REFERENCES:
patent: 5498774 (1996-03-01), Mitsudera et al.
patent: 0 404 190 (1990-06-01), None
patent: 98/54093 (1998-12-01), None
patent: 99/12930 (1999-03-01), None
patent: 99/32447 (1999-07-01), None
patent: 01/14375 (2001-03-01), None
patent: 01/34605 (2001-05-01), None
patent: 02/22601 (2002-03-01), None
patent: 02/066481 (2002-08-01), None
Blain et al., Differential Interaction of the Cyclin-dependent kinase (Cdk) Inhibitor p27kip1 with Cyclin A-Cdk2 and Cyclin D2-Cdk4, The Journal of Biological Chemistry, vol. 272, No. 41, pp. 25863-25872, 1997.
LuValle et al., Cell Cycle Control in Growth Plate Chondrocytes, Frontiers in Bioscience 5, d493-503, May 2001.
Simone, Oncology: Introduction, Cecil Textbook of Medicine, 20th Edition, vol. 1, pp. 1004-1010, 1996.
Traxler, Protein Tyrosine Kinase Inhibitors in cancer treatment, Expert Opinion on Therapeutic Patents, 7(6):571-588, 1997.
West, Solid Solutions, Solid state chemistry and it's applications, Wiley, New York, pp. 358 and 365, 1988.
Vippagunta et al., Crystalline solids, Advanced Drug Delivery Reviews, 48 (2001), pp. 3-26, 2001.
Ulrich, Crystallization, Kirk-Othmer Encyclopedia of Chemical Technology, vol. 8, pp. 113-120, (http://www.mrw.interscience.wiley.com/kirk/articles/crysrous.a01/sect4-fs.html) Aug. 2002.
Teixeira et al., CDK2 is a Target for Retinoic Acid-Mediated Growth Inhibition in MCF-7 Human Breast Cancer Cells, Molecular Endocrinology, vol. 11, No. 9, pp. 1191-1202, 1997.
Davis et al., “Prevent of Chemotherapy-Induced Alopecia in Rats by CDK Inhibitors,”Science,2001, V291, pp. 134-137.
Katritzki, A.R. et al., “Syntheses of 2-Alkylamino- and 2-Dialkylamino-4,6-diarylpyridines and 2,4,6-Trisubstituted Pyrimidines Using Solid-Phase-Bound Chalcones,”Journal of Combinatoral Chemistry,2000, V2, N2, pp. 182-185.
Henke, B.R. et al., “2-Amino-4,6-Diarylpyridines as Novel Ligands for the Estrogen Receptor,”Bioorganic&Medcinal Chemistry Letters,2001, V11, N14, pp. 1939-1942.
Katritzky, “Benzotriazole-assisted preparations of 2-(substituted amino)pyridines and pyrid-2-ones,”J. Org. Chem.,1997, V62, N18, pp. 6210-6214.
Chemical Abstracts, vol. 115, No. 3, 1991, Columbus, Ohio.
Belstein Institut zur Forderung der Chemischen Wissenschaften, Frankfurt am Main, DE; XP002203368, 1961.
Chemical Abstracts, vol. 100, No. 25, 1984, Columbus, Ohio.
Belstein Institut zur Forderung der Chemischen Wissenschaften, Frankfurt am Main, DE; XP002203369, 1971.
Belstein Institut zur Forderung der Chemischen Wissenschaften, Frankfurt am Main, DE; XP002203370, 1970.
Badiang Jennifer G.
Dickerson Scott Howard
Harris Philip Anthony
Jung David Kendall
Peel Michael Robert
Coulter Kathryn L.
Lemanowicz John L.
Rao Deepak
SmithKline Beecham Corporation
LandOfFree
Pyrazolopyridazine derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrazolopyridazine derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrazolopyridazine derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3901132